Triple negatif meme kanserlerinde nm23 ekspresyonunun prognostik önemi
Loading...
Files
Date
2012
Authors
Çubukçu, Erdem
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Meme kanseri dünyada kadınlarda ensık görülen kanserdir. Kadınlarda kanser ölümlerinin 2.ensık sebebidir ve 40ile 59 yaşlarındaki kadınlarda ölümün ana sebebidir. Meme kanseri için en önemli risk faktörleri yaş, cinsiyet, üreme geçmişi, hormonal faktörler ve aile öyküsüdür. Gen ekspresyon çalışmaları birkaç farklı meme kanseri alt tipini belirledi. Böylece Östrojen reseptörünün negatif (ER) olduğu üç ana alt grup, basal like, Human epidermal growth factor-2 (HER2) pozitif ve normal-like; ve ER pozitif iki alt tip luminal A ve luminal B içerir.Triple negatif meme kanseri en sık değerlendirilen üç biyolojikmarkerların ekspresyonunun yokluğu ile tanımlanır (Östrojen reseptörü (ER), progesteron reseptörü (PR), Human epidermal growth factor-2 (HER2). Triple negatif meme kanseri diğer meme kanseri alt tiplerinden daha kötü prognozlu, daha yüksek relaps oranları ile karakterizedir. Kanser hastalarında ölümün en önde gelen nedeni metastatik yayılmadır. Metastaz supresör genler (tumör supresör genlerden farklı) primer tümörün büyümesini etkilemeksizin tümörün invivo metastattik yayılma kapasitesini kontrol eden genler olarak tanımlanır. Bu genlerin ilki olan non metastasis supressör genes 23 (nm23) ilk olarak 1988 te tanımlandı. Çalışmamızda retrospektif olarak triple negativ meme kanserli hastalarda tümör dokusu nm23 gen düzeyi ile hastalıksız sağkalım ve genel sağkalım arasındaki ilişki araştırılmıştır. Çalışmaya toplam 81 hasta alındı. Hastaların yaş ortalaması 51.93 ± 11.14 (21- 73) yıl olarak bulundu. Her iki grup karşılaştırıldığında nm23 ekspresyon düzeylerinde istatiksel anlamlı farklılık saptanmadı. c-erB2 negatif grupta genel sağkalım 63.77 ± 3.41 ay, pozitif grupta ise 76.80 ± 8.09 ay bulunmuştur. Her iki grup arasında istatiksel fark saptanmamıştır.Çalışmamızda nm23 düzeyi negatif ve pozitif hastalarda genel sağkalım ve hastalıksız sağkalım sürelerinde farklılık saptanmış olsa da istatiksel fark saptanamamıştır.
Breast cancer is the most common female cancer in the world, the second most common cause of cancer death in women, and the main cause of death in women ages 40 to 59 years. Important risk factors for breast cancer are age, gender, reproductive history, hormonal factors, and family history. Gene expression studies have identified several distinct breast cancer subtypes. These include three main subtypes of estrogen receptor (ER)-negative tumors, basal-like, human epidermal growth factor receptor-2 (HER2)-enriched, and normal-like; and two subtypes of ER-positive tumors, luminal A and luminal B.Triple negative breast cancer is defined as lack of expression of the three most commonly evaluated biomarkers (the estrogen receptor [ER], progesterone receptor [PR], and the human epidermal growth factor receptor 2 [HER2] protein). Triple-negative breast cancer is generally characterized by higher relapse rates and poorer prognosis than other breast cancer subtypes. Metastatic dissemination represents a leading cause of death in cancer patients. Metastasis suppressor genes are defined by their capacity to control metastatic dissemination in vivo without affecting growth of the primary tumor unlike tumor suppressor genes. The first of these metastasis suppressor genes, NM23, was identified in 1988. In our study we retrospectively search the relationship between nm23 gene levels and disease free survival and survival in triple negative breast cancers. A total of 81 patients participated in the study. The mean age of patients was 51.93 ± 11:14 (21- 73) years. Patients were divided into 2 groups, including c-erB2 positive and c-erB2 negative. There wasn't statistically significant difference regarding nm23 expression levels between two groups. Overall survival was 63.77 ± 3.41 months and 76.80 ± 8.09 months in c-erB2 negative and c-erB2 positive groups respectively. Statistically significant difference wasn't detected between two groups regarding oveall survival.In our study, difference regarding overall survival and disease-free survival between nm23 negative and nm23 positive patients was detected but this difference was not statistically significant.
Breast cancer is the most common female cancer in the world, the second most common cause of cancer death in women, and the main cause of death in women ages 40 to 59 years. Important risk factors for breast cancer are age, gender, reproductive history, hormonal factors, and family history. Gene expression studies have identified several distinct breast cancer subtypes. These include three main subtypes of estrogen receptor (ER)-negative tumors, basal-like, human epidermal growth factor receptor-2 (HER2)-enriched, and normal-like; and two subtypes of ER-positive tumors, luminal A and luminal B.Triple negative breast cancer is defined as lack of expression of the three most commonly evaluated biomarkers (the estrogen receptor [ER], progesterone receptor [PR], and the human epidermal growth factor receptor 2 [HER2] protein). Triple-negative breast cancer is generally characterized by higher relapse rates and poorer prognosis than other breast cancer subtypes. Metastatic dissemination represents a leading cause of death in cancer patients. Metastasis suppressor genes are defined by their capacity to control metastatic dissemination in vivo without affecting growth of the primary tumor unlike tumor suppressor genes. The first of these metastasis suppressor genes, NM23, was identified in 1988. In our study we retrospectively search the relationship between nm23 gene levels and disease free survival and survival in triple negative breast cancers. A total of 81 patients participated in the study. The mean age of patients was 51.93 ± 11:14 (21- 73) years. Patients were divided into 2 groups, including c-erB2 positive and c-erB2 negative. There wasn't statistically significant difference regarding nm23 expression levels between two groups. Overall survival was 63.77 ± 3.41 months and 76.80 ± 8.09 months in c-erB2 negative and c-erB2 positive groups respectively. Statistically significant difference wasn't detected between two groups regarding oveall survival.In our study, difference regarding overall survival and disease-free survival between nm23 negative and nm23 positive patients was detected but this difference was not statistically significant.
Description
Keywords
Onkoloji, Gen ifadesi, Genler, Meme neoplazmları, Neoplazmlar, Prognoz, Sağkalım, Oncology, Gene expression, Genes, Breast neoplasms, Neoplasms, Prognosis, Survival
Citation
Çubukçu, E. (2012). Triple negatif meme kanserlerinde nm23 ekspresyonunun prognostik önemi. Yayınlanmamış uzmanlık tezi. Uludağ Üniversitesi Tıp Fakültesi.